Literature DB >> 24468629

Improved storage stability and immunogenicity of hepatitis B vaccine after spray-freeze drying in presence of sugars.

W F Tonnis1, J-P Amorij2, M A Vreeman1, H W Frijlink1, G F Kersten3, W L J Hinrichs4.   

Abstract

The current hepatitis B vaccines need to be stored and transported under refrigerated conditions (2-8°C). This dependence on a cold-chain is highly challenging in areas where hepatitis B virus infections are endemic. To decrease the cold-chain dependency, powder formulations of the hepatitis B surface antigen (HBsAg) without aluminum were prepared by spray-freeze drying in the presence of either inulin or a combination of dextran and trehalose. The stability of HBsAg in the amorphous powder formulations was strongly improved during storage both at room temperature and at an elevated temperature (60°C), compared to a liquid plain and an aluminum hydroxide adjuvanted HBsAg formulation. Immunogenicity studies in mice showed that reconstituted powder formulations induced higher IgG immune responses after intramuscular administration than those induced after administration of unprocessed plain antigen. Although the immune response was not as high as after administration of aluminum adjuvanted HBsAg, the immune response to the reconstituted vaccines shifted towards a more balanced Th1/Th2 response compared to the aluminum containing HBsAg formulation.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dextran; Hepatitis B surface antigen; Inulin; Powder formulation; Stabilization; Trehalose

Mesh:

Substances:

Year:  2014        PMID: 24468629     DOI: 10.1016/j.ejps.2014.01.005

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  11 in total

1.  Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.

Authors:  Lukai Zhai; Rashi Yadav; Nitesh K Kunda; Dana Anderson; Elizabeth Bruckner; Elliott K Miller; Rupsa Basu; Pavan Muttil; Ebenezer Tumban
Journal:  Antiviral Res       Date:  2019-03-26       Impact factor: 5.970

2.  Development of a highly thermostable, adjuvanted human papillomavirus vaccine.

Authors:  Kimberly J Hassett; Natalie M Meinerz; Florian Semmelmann; Megan C Cousins; Robert L Garcea; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2015-05-18       Impact factor: 5.571

3.  Stabilization and application of spray-dried tannase from Aspergillus fumigatus CAS21 in the presence of different carriers.

Authors:  Rayza Morganna Farias Cavalcanti; Marcelo Luís Lombardi Martinez; Wanderley Pereira Oliveira; Luís Henrique Souza Guimarães
Journal:  3 Biotech       Date:  2020-03-25       Impact factor: 2.406

4.  Predictors of Infant Hepatitis B Immunization in Cameroon: Data to Inform Implementation of a Hepatitis B Birth Dose.

Authors:  Jodie Dionne-Odom; Andrew O Westfall; Divine Nzuobontane; Michael J Vinikoor; Gregory Halle-Ekane; Thomas Welty; Alan T N Tita
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

5.  A stable live bacterial vaccine.

Authors:  Nitesh K Kunda; Denis Wafula; Meilinn Tram; Terry H Wu; Pavan Muttil
Journal:  Eur J Pharm Biopharm       Date:  2016-03-25       Impact factor: 5.571

Review 6.  Developments in the formulation and delivery of spray dried vaccines.

Authors:  Gaurav Kanojia; Rimko Ten Have; Peter C Soema; Henderik Frijlink; Jean-Pierre Amorij; Gideon Kersten
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 7.  Virus-like particle vaccines: immunology and formulation for clinical translation.

Authors:  Braeden Donaldson; Zabeen Lateef; Greg F Walker; Sarah L Young; Vernon K Ward
Journal:  Expert Rev Vaccines       Date:  2018-09-19       Impact factor: 5.217

8.  Silica Vesicle Nanovaccine Formulations Stimulate Long-Term Immune Responses to the Bovine Viral Diarrhoea Virus E2 Protein.

Authors:  Karishma T Mody; Donna Mahony; Antonino S Cavallaro; Jun Zhang; Bing Zhang; Timothy J Mahony; Chengzhong Yu; Neena Mitter
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

9.  Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice.

Authors:  Katie Amssoms; Philip A Born; Max Beugeling; Ben De Clerck; Ellen Van Gulck; Wouter L J Hinrichs; Henderik W Frijlink; Niels Grasmeijer; Guenter Kraus; Roger Sutmuller; Kenny Simmen; Lieven Baert
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

10.  Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study.

Authors:  Max Beugeling; Katie Amssoms; Freek Cox; Ben De Clerck; Ellen Van Gulck; Jeroen A Verwoerd; Guenter Kraus; Dirk Roymans; Lieven Baert; Henderik W Frijlink; Wouter L J Hinrichs
Journal:  Pharmaceutics       Date:  2019-10-03       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.